Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Laboratory of Drug Delivery Technology, Dept. of Drug Sciences, University of Catania, Catania, Italy.
Prog Lipid Res. 2017 Oct;68:1-11. doi: 10.1016/j.plipres.2017.07.001. Epub 2017 Aug 1.
Solid lipid nanoparticle (SLN), nanostructured lipid carriers (NLC) and hybrid nanoparticles, have gained increasing interest as drug delivery systems because of their potential to load and release drugs from the Biopharmaceutical classification system (BCS) of class II (low solubility and high permeability) and of class IV (low solubility and low permeability). Lipid properties (e.g. high solubilizing potential, biocompatibility, biotolerability, biodegradability and distinct route of absorption) contribute for the improvement of the bioavailability of these drugs for a set of administration routes. Their interest continues to grow, as translated by the number of patents being field worldwide. This paper discusses the recent advances on the use of SLN, NLC and lipid-polymer hybrid nanoparticles for the loading of lipophilic, poorly water-soluble and poorly permeable drugs, being developed for oral, topical, parenteral and ocular administration, also discussing the industrial applications of these systems. A review of the patents filled between 2014 and 2017, concerning the original inventions of lipid nanocarriers, is also provided.
固体脂质纳米粒(SLN)、纳米结构脂质载体(NLC)和混合纳米粒作为药物传递系统越来越受到关注,因为它们有可能从生物药剂学分类系统(BCS)的 II 类(低溶解度和高通透性)和 IV 类(低溶解度和低通透性)载药和释药。脂质性质(例如高增溶能力、生物相容性、生物耐受性、可生物降解性和独特的吸收途径)有助于提高这些药物通过一系列给药途径的生物利用度。这一点可以从全世界申请的专利数量上得到证实。本文讨论了 SLN、NLC 和脂质-聚合物混合纳米粒在负载脂溶性、低水溶性和低渗透性药物方面的最新进展,这些药物正在开发用于口服、局部、肠胃外和眼部给药,并讨论了这些系统的工业应用。还提供了对 2014 年至 2017 年期间提交的专利的综述,这些专利涉及脂质纳米载体的原始发明。